BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, is joining the Digital Therapeutics Alliance. A nonprofit association of industry leaders, the alliance is dedicated to driving awareness and adoption of digital therapies. MINDCURE announced that, as part of the alliance, the company is committed to providing value and reimbursement, policy and regulation, and awareness to educate the broader health-care industry about the benefits of including new technologies in current treatment regimes. Collaboration with the alliance is a strategic move as MINDCURE works to position iSTRYM, its proprietary software application, as an industry standard distribution network for science-based, evidence-backed protocols and artificial intelligence (“AI”) data systems. The application is designed optimize the healing journey for patients and clinicians by providing data-driven support before, during and after therapy sessions. “Joining the Digital Therapeutics Alliance is a huge opportunity for our company to be at the forefront of how digital technology is adopted and regulated in the mental health industry,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “We look forward to collaborating with leaders in the space to help define the future as we invest in and research the potential of digital therapeutics, with a focus on psychedelics. . . . Digital therapeutics is the future of mental health care, and there’s a need to balance the fast adoption of new technologies with thoughtful regulation. This partnership solidifies an industry leadership role for the company as we continue to execute on our strategic research and development goals.”

To view the full press release, visit https://ibn.fm/fsiY0

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork